- Home
- GPRO vs EXEL Comparison
GPRO vs EXEL Comparison
Compare GPRO & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRO
- EXEL
- Stock Information
- Founded
- GPRO 2004
- EXEL 1994
- Country
- GPRO United States
- EXEL United States
- Employees
- GPRO N/A
- EXEL N/A
- Industry
- GPRO Industrial Machinery/Components
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GPRO Consumer Discretionary
- EXEL Health Care
- Exchange
- GPRO Nasdaq
- EXEL Nasdaq
- Market Cap
- GPRO 118.4M
- EXEL 11.3B
- IPO Year
- GPRO 2014
- EXEL 2000
- Fundamental
- Price
- GPRO $0.74
- EXEL $46.20
- Analyst Decision
- GPRO Hold
- EXEL Buy
- Analyst Count
- GPRO 1
- EXEL 18
- Target Price
- GPRO $1.50
- EXEL $43.00
- AVG Volume (30 Days)
- GPRO 5.2M
- EXEL 3.6M
- Earning Date
- GPRO 08-05-2025
- EXEL 08-05-2025
- Dividend Yield
- GPRO N/A
- EXEL N/A
- EPS Growth
- GPRO N/A
- EXEL 237.58
- EPS
- GPRO N/A
- EXEL 2.20
- Revenue
- GPRO $780,312,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- GPRO N/A
- EXEL $9.37
- Revenue Next Year
- GPRO $6.79
- EXEL $11.05
- P/E Ratio
- GPRO N/A
- EXEL $20.94
- Revenue Growth
- GPRO N/A
- EXEL 24.49
- 52 Week Low
- GPRO $0.40
- EXEL $21.82
- 52 Week High
- GPRO $1.76
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- GPRO 47.74
- EXEL 59.21
- Support Level
- GPRO $0.67
- EXEL $43.32
- Resistance Level
- GPRO $0.95
- EXEL $44.48
- Average True Range (ATR)
- GPRO 0.06
- EXEL 1.54
- MACD
- GPRO -0.02
- EXEL 0.12
- Stochastic Oscillator
- GPRO 26.26
- EXEL 47.90
About GPRO GoPro Inc.
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.